Arkolith/Insider Trading/APRE/Form 4

Gilad Oren

President/CEO, DirectorAprea Therapeutics, Inc. (APRE) · full profile →Form 4 · filed Dec 11, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 10, 2025Buy(P)21K——21K
Dec 10, 2025Buy(P)21K$1.17$25K21K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-120152) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML